Adaptive Biotechnologies Corporation (ADPT)

Market Cap	2.17B +96.4%
Revenue (ttm)	276.98M +54.8%
Net Income	-59.50M
EPS	-0.39
Shares Out	153.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,303,014
Open	14.29
Previous Close	14.53
Day's Range	14.02 - 14.52
52-Week Range	6.78 - 20.76
Beta	2.30
Analysts	Strong Buy
Price Target	17.78 (+26.28%)
Earnings Date	May 5, 2026

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minima...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 624
• Stock Exchange: NASDAQ
• Ticker Symbol: ADPT
• Website: https://www.adaptivebiotech.com

Financial Performance

In 2025, Adaptive Biotechnologies's revenue was $276.98 million, an increase of 54.77% compared to the previous year's $178.96 million. Losses were -$59.50 million, -62.69% less than in 2024.

Analyst Summary

According to 9 analysts, the average rating for ADPT stock is "Strong Buy." The 12-month stock price target is $17.78, which is an increase of 26.28% from the latest price.

Price Target

$17.78

(26.28% upside)

Analyst Consensus: Strong Buy